<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31575928</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Reducing EphA4 before disease onset does not affect survival in a mouse model of Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>14112</StartPage><MedlinePgn>14112</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">14112</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-019-50615-0</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects motor neurons resulting in severe neurological symptoms. Previous findings of our lab suggested that the axonal guidance tyrosine-kinase receptor EphA4 is an ALS disease-modifying gene. Reduction of EphA4 from developmental stages onwards rescued a motor neuron phenotype in zebrafish, and heterozygous deletion before birth in the SOD1<sup>G93A</sup> mouse model of ALS resulted in improved survival. Here, we aimed to gain more insights in the cell-specific role of decreasing EphA4 expression in addition to timing and amount of EphA4 reduction. To evaluate the therapeutic potential of lowering EphA4 later in life, we ubiquitously reduced EphA4 levels to 50% in SOD1<sup>G93A</sup> mice at 60 days of age, which did not modify disease parameters. Even further lowering EphA4 levels ubiquitously or in neurons, did not improve disease onset or survival. These findings suggest that lowering EphA4 as target in ALS may suffer from a complex therapeutic time window. In addition, the complexity of the Eph-ephrin signalling system may also possibly limit the therapeutic potential of such an approach in ALS. We suggest here that a specific EphA4 knockdown in adulthood may have a limited therapeutic potential for ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ru&#xe9;</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5415-5153</Identifier><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timmers</LastName><ForeName>Mieke</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenaerts</LastName><ForeName>Annette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smolders</LastName><ForeName>Silke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poppe</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Boer</LastName><ForeName>Antina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Den Bosch</LastName><ForeName>Ludo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Leuven, Campus Gasthuisberg, Department of Neurology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robberecht</LastName><ForeName>Wim</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Leuven, Campus Gasthuisberg, Department of Neurology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemmens</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), Leuven, Belgium. robin.lemmens@uzleuven.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium. robin.lemmens@uzleuven.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Leuven, Campus Gasthuisberg, Department of Neurology, Leuven, Belgium. robin.lemmens@uzleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D036122">Receptor, EphA4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036122" MajorTopicYN="N">Receptor, EphA4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015027" MajorTopicYN="N">Zebrafish</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31575928</ArticleId><ArticleId IdType="pmc">PMC6773754</ArticleId><ArticleId IdType="doi">10.1038/s41598-019-50615-0</ArticleId><ArticleId IdType="pii">10.1038/s41598-019-50615-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lat Scl Fr. 2014;15:610&#x2013;617. doi: 10.3109/21678421.2014.959024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka, M., Akimoto, M., Palumbo, J. &amp; Sakata, T. A Double-Blind, Parallel-Group, Placebo-Controlled, 24-Week, Exploratory Study of Edaravone (MCI-186) for the Treatment of Advanced Amyotrophic Lateral Sclerosis (ALS). Neurology86 (2016).</Citation></Reference><Reference><Citation>Tanaka, M., Sakata, T., Palumbo, J. &amp; Akimoto, M. A 24-Week, Phase III, Double-Blind, Parallel-Group Study of Edaravone (MCI-186) for Treatment of Amyotrophic Lateral Sclerosis (ALS). Neurology86 (2016).</Citation></Reference><Reference><Citation>Taylor JP, Brown RH, Jr., Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10:661&#x2013;670. doi: 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Regal L, et al. The G93C mutation in superoxide dismutase 1 - Clinicopathologic phenotype and prognosis. Arch Neurol-Chicago. 2006;63:262&#x2013;267. doi: 10.1001/archneur.63.2.262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.63.2.262</ArticleId><ArticleId IdType="pubmed">16476815</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogh I, et al. Age at onset in sod1-mediated amyotrophic lateral sclerosis shows familiality. Neurogenetics. 2007;8:235&#x2013;236. doi: 10.1007/s10048-007-0092-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-007-0092-2</ArticleId><ArticleId IdType="pubmed">17549529</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoecke A, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med. 2012;18:1418&#x2013;1422. doi: 10.1038/nm.2901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2901</ArticleId><ArticleId IdType="pubmed">22922411</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell. 2008;133:38&#x2013;52. doi: 10.1016/j.cell.2008.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.03.011</ArticleId><ArticleId IdType="pubmed">18394988</ArticleId></ArticleIdList></Reference><Reference><Citation>Greferath U, Canty AJ, Messenger J, Murphy M. Developmental expression of EphA4-tyrosine kinase receptor in the mouse brain and spinal cord. Mech Dev. 2002;119(Suppl 1):S231&#x2013;238. doi: 10.1016/S0925-4773(03)00122-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0925-4773(03)00122-9</ArticleId><ArticleId IdType="pubmed">14516691</ArticleId></ArticleIdList></Reference><Reference><Citation>Murai KK, et al. Targeting the EphA4 receptor in the nervous system with biologically active peptides. Mol Cell Neurosci. 2003;24:1000&#x2013;1011. doi: 10.1016/j.mcn.2003.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2003.08.006</ArticleId><ArticleId IdType="pubmed">14697664</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay ME, et al. Localization of EphA4 in axon terminals and dendritic spines of adult rat hippocampus. J Comp Neurol. 2007;501:691&#x2013;702. doi: 10.1002/cne.21263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.21263</ArticleId><ArticleId IdType="pubmed">17299751</ArticleId></ArticleIdList></Reference><Reference><Citation>Filosa A, et al. Neuron-glia communication via EphA4/ephrin-A3 modulates LTP through glial glutamate transport. Nat Neurosci. 2009;12:1285&#x2013;1292. doi: 10.1038/nn.2394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2394</ArticleId><ArticleId IdType="pmc">PMC3922060</ArticleId><ArticleId IdType="pubmed">19734893</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmbacher F, Schneider-Maunoury S, Topilko P, Tiret L, Charnay P. Targeting of the EphA4 tyrosine kinase receptor affects dorsal/ventral pathfinding of limb motor axons. Development. 2000;127:3313&#x2013;3324.</Citation><ArticleIdList><ArticleId IdType="pubmed">10887087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemmens R, Jaspers T, Robberecht W, Thijs VN. Modifying expression of EphA4 and its downstream targets improves functional recovery after stroke. Hum Mol Genet. 2013;22:2214&#x2013;2220. doi: 10.1093/hmg/ddt073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt073</ArticleId><ArticleId IdType="pubmed">23418304</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldshmit Y, Galea MP, Wise G, Bartlett PF, Turnley AM. Axonal regeneration and lack of astrocytic gliosis in EphA4-deficient mice. J Neurosci. 2004;24:10064&#x2013;10073. doi: 10.1523/JNEUROSCI.2981-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2981-04.2004</ArticleId><ArticleId IdType="pmc">PMC6730186</ArticleId><ArticleId IdType="pubmed">15537875</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro KM, et al. EphA4 receptor tyrosine kinase is a modulator of onset and disease severity of experimental autoimmune encephalomyelitis (EAE) PLoS One. 2013;8:e55948. doi: 10.1371/journal.pone.0055948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0055948</ArticleId><ArticleId IdType="pmc">PMC3563632</ArticleId><ArticleId IdType="pubmed">23390555</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling Karen K., Jackson Michaela, Alkam Duah, Liu Dawei, Allaire Norm, Sun Chao, Kiaei Mahmoud, McCampbell Alexander, Rigo Frank. Antisense-mediated reduction of EphA4 in the adult CNS does not improve the function of mice with amyotrophic lateral sclerosis. Neurobiology of Disease. 2018;114:174&#x2013;183. doi: 10.1016/j.nbd.2018.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.03.002</ArticleId><ArticleId IdType="pubmed">29518482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Cooper LT, Boyd AW, Bartlett PF. Decreased signalling of EphA4 improves functional performance and motor neuron survival in the SOD1(G93A) ALS mouse model. Sci Rep. 2018;8:11393. doi: 10.1038/s41598-018-29845-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-29845-1</ArticleId><ArticleId IdType="pmc">PMC6065374</ArticleId><ArticleId IdType="pubmed">30061574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B, et al. Potent and Selective EphA4 Agonists for the Treatment of ALS. Cell Chem Biol. 2017;24:293&#x2013;305. doi: 10.1016/j.chembiol.2017.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2017.01.006</ArticleId><ArticleId IdType="pmc">PMC6522132</ArticleId><ArticleId IdType="pubmed">28196613</ArticleId></ArticleIdList></Reference><Reference><Citation>Willson CA, et al. Upregulation of EphA receptor expression in the injured adult rat spinal cord. Cell Transplant. 2002;11:229&#x2013;239. doi: 10.3727/096020198389997.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096020198389997</ArticleId><ArticleId IdType="pubmed">12075988</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey D, et al. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci. 2000;20:2534&#x2013;2542. doi: 10.1523/JNEUROSCI.20-07-02534.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-07-02534.2000</ArticleId><ArticleId IdType="pmc">PMC6772256</ArticleId><ArticleId IdType="pubmed">10729333</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun S, Santos AF, Saxena S, Xu L, Caroni P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci. 2006;9:408&#x2013;419. doi: 10.1038/nn1653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1653</ArticleId><ArticleId IdType="pubmed">16474388</ArticleId></ArticleIdList></Reference><Reference><Citation>Takata M, et al. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br J Pharmacol. 2013;170:341&#x2013;351. doi: 10.1111/bph.12277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12277</ArticleId><ArticleId IdType="pmc">PMC3834758</ArticleId><ArticleId IdType="pubmed">23763343</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonges L, et al. Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia. 2014;62:217&#x2013;232. doi: 10.1002/glia.22601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22601</ArticleId><ArticleId IdType="pubmed">24311453</ArticleId></ArticleIdList></Reference><Reference><Citation>Ru&#xe9; L, et al. Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2019;7:114. doi: 10.1186/s40478-019-0759-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0759-6</ArticleId><ArticleId IdType="pmc">PMC6626434</ArticleId><ArticleId IdType="pubmed">31300041</ArticleId></ArticleIdList></Reference><Reference><Citation>Festuccia C, et al. UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice. Oncotarget. 2018;9:24347&#x2013;24363. doi: 10.18632/oncotarget.25272.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.25272</ArticleId><ArticleId IdType="pmc">PMC5966254</ArticleId><ArticleId IdType="pubmed">29849945</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler. 2010;11:38&#x2013;45. doi: 10.3109/17482960903545334.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903545334</ArticleId><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>